Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

STC-004 was well-tolerated at all doses tested, SiteOne previously reported. Eli Lilly stated STC-004 is "Phase II ready" and “may represent a next-generation, non-opioid treatment for patients ...

Eli Lilly's acquisition of SiteOne Therapeutics and STC-004 brings a once-daily NaV1.8 candidate, with early promising results but limited clinical data so far.

Called STC-004, the treatment is a a Nav1.8 inhibitor that is ready for Phase 2 testing. Lilly said STC-004 might represent a next-generation, non-opioid treatment for chronic pain.

STC-004 belongs to a class of drugs known as Nav1.8 inhibitors that targets the channels involved in transmitting pain signals. Opioids, on the other hand, ...

The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. STC-004 may represent a next-generation, non-opioid treatment for patients suffering ...

SiteOne’s STC-004 is an oral small molecule designed to target NaV1.8. In February, SiteOne reported Phase 1 results showing STC-004 was rapidly absorbed with a half-life that supports once ...

Like Vertex's Journavx (suzetrigine), cleared by the FDA in February for moderate-to-severe acute pain, STC-004 is an oral inhibitor of the NaV1.8 sodium channel, blocking a pain-signalling ...

Perhaps STC-004 will flop in upcoming clinical trials. But there's something important to highlight about Eli Lilly that this acquisition brings to light. Beyond the weight management market.

Upon the completion of the deal, the company expects to continue the development of STC-004 along with the SiteOne team, paving way for advancement of new non-opioid medicines for pain management.